DavidFeifelMDPhD

Psychiatry • La Jolla, CA

Psychopharmacology, Psychosomatic Medicine

Physician

Join to view full profile

Dr. Feifel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Feifel's full profile

Already have an account?

Office
3252 Holiday Ct
Ste 112
La Jolla, CA 92037
Phone+1 858-412-4130

Fax+1 858-412-5088

Education & Training

University of California (San Diego) Medical CenterResidency, Psychiatry, 1992 - 1995
University of Toronto Faculty of MedicineClass of 1991

Certifications & Licensure

CA State Medical License 1992 - 2026
American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes Start of enrollment: 2006 Dec 01
Completed
Phase 4
Oxytocin Add on Study for Stable Schizophrenic Patients Start of enrollment: 2008 Mar 01
Terminated
Not Applicable
Oxytocin Add-on Study for Stable Anxiety Patients Start of enrollment: 2009 Feb 01
Terminated
Not Applicable
Oxytocin Add-on for Stable Depressed Patients Start of enrollment: 2010 Oct 01
Terminated
Not Applicable
Antipsychotic Effects of Oxytocin Start of enrollment: 2011 Jun 01
Terminated
Not Applicable
Evaluation of Deep Transcranial Magnetic Stimulation (DTMS) With the H-ADD Coil as an Aid to Smoking Cessation. Start of enrollment: 2014 Aug 20
Completed
Phase 3
Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia Start of enrollment: 2012 Mar 01
Terminated
Not Applicable
A Safety & Efficacy Study With Deep Transcranial Magnetic Stimulation for the Treatment of Post-Traumatic Stress Disorder (PTSD) Start of enrollment: 2016 Nov 17
Terminated
Not Applicable
Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder Start of enrollment: 2017 Nov 27
Completed
Not Applicable
Testing the Value of Smartphone Assessments of People With Mood Disorders Start of enrollment: 2017 Aug 08
Completed
Post Hoc Analysis and Clinical Data Collection for Subjects Tested With Brain Network Activation (BNA™) Technology Start of enrollment: 2018 May 01
Recruiting
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression Start of enrollment: 2019 Mar 01
Completed
Phase 2
Combining H1-Coil Deep Transcranial Magnetic Stimulation (dTMS) and App-guided CBT in Subjects With Major Depression Disorder (MDD) Start of enrollment: 2019 Aug 26
Recruiting
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression Start of enrollment: 2020 Aug 10
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.
Guy M Goodwin, Scott T Aaronson, Oscar Alvarez, Robin Carhart-Harris, Jamie Chai-Rees
Journal of Affective Disorders. 2025-03-01
Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society...
Nicholas T Trapp, Anthony Purgianto, Joseph J Taylor, Manpreet K Singh, Lindsay M Oberman
Clinical Neurophysiology. 2025-02-01
Effects of four-week intranasal oxytocin administration on large-scale brain networks in older adults.
Peiwei Liu, Tian Lin, Håkan Fischer, David Feifel, Natalie C Ebner
Neuropharmacology. 2024-12-01

Press Mentions

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)December 16th, 2024
The Wellness Industry Is Sneaking Medication Stigma Back into the Mainstream — & Here’s How to Fight ItMay 13th, 2023
Dosages, Side Effects, and More – Forbes HealthApril 19th, 2023
Join now to see all

Grant Support

Neurotensin-1 Receptor As A Therapeutic Target For SchizophreniaNational Institute Of Mental Health2009–2012
1/2-Anti-Psychotic Effects Of OxytocinNational Institute Of Mental Health2011
A Novel Animal Model Of Relevance To SchizophreniaNational Institute Of Mental Health2005–2009
Antipsychotic-Like Drug Effects Of NeurotensinNational Institute Of Mental Health2002–2004
Olanzapine + Devalproex VS Placebo + DevalproexNational Center For Research Resources2000–2002

External Links

Kadima Neuropsychiatry Institutehttp://www.kadimanp.com

DavidFeifelMDPhD

Dr. Feifel is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

External Links

Viewing the full profile is available to verified healthcare professionals only.